Novel regimens prior to autologous stem cell transplantation for the management of adults with relapsed/refractory non-Hodgkin lymphoma and Hodgkin lymphoma: alternatives to BEAM conditioning

References

• Kuruvilla J. Standard therapy of advanced Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program. 2009;15:497–506.
   Google Scholar
• Josting A, Nogova L, Franklin J, et al. Salvage radiotherapy in patients with relapsed and refractory Hodgkin’s lymphoma: a retrospective analysis from the German Hodgkin lymphoma study group. J Clin Oncol. 2005;23:1522–1529.
   PubMed Web of Science ®Google Scholar
• Ardeshna KM, Kakouros N, Qian W, et al. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. Br J Haematol. 2005;130:363–372.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• Bierman PJ, Armitage JO. Looking back (and ahead) at salvage treatment for non-Hodgkin lymphoma. Oncology (Williston Park). 2009;23:619, 625.
   Google Scholar
• Seshadri T, Kuruvilla J, Crump M, et al. Salvage therapy for relapsed/refractory diffuse large B cell lymphoma. Biol Blood Marrow Transplant. 2008;14:259–267.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med. 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Unger JM, Cook JR, et al. Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma. N Engl J Med. 2013;369:1681–1690.
   PubMed Web of Science ®Google Scholar
• Gisselbrecht BG C, Laurent G, Gill DS, et al. Maintenance with rituximab after autologous stem cell transplantation in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL): CORAL final analysis. J Clin Oncol. 2011;29:4184–4190.
   Google Scholar
• Crump M, Kuruvilla J, Couban S, et al. Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol. 2014;32:3490–3496.
   PubMed Web of Science ®Google Scholar
• van Imhoff GW, McMillan A, Matasar MJ. Ofatumumab versus rituximab salvage chemoimmunotherapy in relapsed or refractory diffuse large B-cell lymphoma: the Orcharrd study (OMB110928). Blood(Suppl.). 2014;124:630 (abstr 630).
   Google Scholar
• Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet. 1993;341:1051–1054.
   PubMed Web of Science ®Google Scholar
• Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin’s disease: a randomised trial. Lancet. 2002;359:2065–2071.
   PubMed Web of Science ®Google Scholar
• Kenkre VP, Smith SM. Management of relapsed diffuse large B-cell lymphoma. Curr Oncol Rep. 2008;10:393–403.
   PubMed Web of Science ®Google Scholar
• Chen YB, Lane AA, Logan BR, et al. Impact of conditioning regimen on outcomes for patients with lymphoma undergoing high-dose therapy with autologous hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2015;21:1046–1053.
   PubMed Web of Science ®Google Scholar
• Isidori A, Piccaluga PP, Loscocco F, et al. High-dose therapy followed by stem cell transplantation in Hodgkin's lymphoma: past and future. Expert Rev Hematol. 2013;6:451–464.
   PubMed Web of Science ®Google Scholar
• Garciaz S, Coso D, Schiano de Collela JM, et al. Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity. Bone Marrow Transplant. 2016;51:319–321.
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan AK, Linch DC, et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood. 1993;81:1137–1145.
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, McMillan A, et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol. 1995;13:588–595.
   PubMed Web of Science ®Google Scholar
• Lumley MA, Milligan DW, Knechtli CJ, et al. High lactate dehydrogenase level is associated with an adverse outlook in autografting for Hodgkin's disease. Bone Marrow Transplant. 1996;17:383–388.
   PubMed Web of Science ®Google Scholar
• Caballero MD, Rubio V, Rifon J, et al. BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors. Bone Marrow Transplant. 1997;20:451–458.
   PubMed Web of Science ®Google Scholar
• Argiris A, Seropian S, Cooper DL. High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol. 2000;11:665–672.
   PubMed Web of Science ®Google Scholar
• Kim JE, Lee DH, Yoo C, et al. BEAM or BuCyE high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: a single center comparative analysis of efficacy and toxicity . Leuk Res. 2011;35:183–187.
   PubMed Web of Science ®Google Scholar
• Nieto Y, Popat U, Anderlini P, et al. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin’s lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013;19:410–417.
   PubMed Web of Science ®Google Scholar
• Spina F, Devizzi L, Dalto S. Long-term outcomes of autologous stem cell transplantation with BEAM conditioning in relapsed non-Hodgkin lymphoma: survival and late toxicities. EBMT Annual Meeting, Istanbul, Turkey. Abstr 0155; 2015.
   Google Scholar
• Caimi PF, William BM, Silva Rondon CH, et al. Comparison of 2 Carmustine-containing regimens in the Rituximab era: excellent outcomes even in poor-risk patients. Biol Blood Marrow Transplant. 2015;21:1926–1931.
   PubMed Web of Science ®Google Scholar
• Berber I, Erkurt MA, Nizam I, et al. Can BuCyE conditioning regimen be an alternative treatment to BEAM at autologous transplantation in malignant lymphoma patients?: a single center experience. Int J Clin Exp Med. 2015;8:16308–16314.
   PubMed Web of Science ®Google Scholar
• Jo JC, Kang BW, Jang G, et al. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity. Ann Hematol. 2008;87:43–48.
   PubMed Web of Science ®Google Scholar
• Sharma A, Kayal S, Iqbal S, et al. Comparison of BEAM versus. LEAM regimen in autologous transplant for lymphoma at AIIMS. Springerplus. 2013;2:489.
   PubMed Web of Science ®Google Scholar
• Salar A, Sierra J, Gandarillas M, et al. Autologous stem cell transplantation for clinically aggressive non-Hodgkin’s lymphoma: the role of preparative regimens. Bone Marrow Transplant. 2001;27:405–412.
   PubMed Web of Science ®Google Scholar
• Mills W, Strang J, Goldstone AH, et al. Dose intensification of etoposide in the BEAM ABMT protocol for malignant lymphoma. Leuk Lymphoma. 1995;17:263–270.
   PubMed Web of Science ®Google Scholar
• Bhatia S, Robison LL, Francisco L, et al. Late mortality in survivors of autologous hematopoietic-cell transplantation: report from the bone marrow transplant survivor study. Blood. 2005;105:4215–4222.
   PubMed Web of Science ®Google Scholar
• Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897–906.
   PubMed Web of Science ®Google Scholar
• Villa D, Crump M, Keating A, et al. Outcome of patients with transformed indolent non-Hodgkin lymphoma referred for autologous stem-cell transplantation. Ann Oncol. 2013;24:1603–1609.
   PubMed Web of Science ®Google Scholar
• Crump M, Smith AM, Brandwein J, et al. High-dose etoposide and melphalan, and autologous bone marrow transplantation for patients with advanced Hodgkin's disease: importance of disease status at transplant. J Clin Oncol. 1993;11:704–711.
   PubMed Web of Science ®Google Scholar
• Taylor PR, Jackson GH, Lennard AL, et al. Autologous transplantation in poor risk Hodgkin’s disease using high dose melphalan/etoposide conditioning with non-cryopreserved marrow rescue. The Newcastle and Northern Region lymphoma group. Br J Cancer. 1993;67:383–387.
   PubMed Web of Science ®Google Scholar
• Seymour LK, Dansey RD, Bezwoda WR. Single high-dose etoposide and melphalan with non-cryopreserved autologous marrow rescue as primary therapy for relapsed, refractory and poor-prognosis Hodgkin's disease. Br J Cancer. 1994;70:526–530.
   PubMed Web of Science ®Google Scholar
• Copelan EA, Penza SL, Pohlman B, et al. Autotransplantation following busulfan, etoposide and cyclophosphamide in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2000;25:1243–1248.
   PubMed Web of Science ®Google Scholar
• Hanel M, Kroger N, Sonnenberg S, et al. Busulfan, cyclophosphamide, and etoposide as high-dose conditioning regimen in patients with malignant lymphoma. Ann Hematol. 2002;81:96–102.
   PubMed Web of Science ®Google Scholar
• Zhang H, Graiser M, Hutcherson DA, et al. Pharmacokinetic-directed high-dose busulfan combined with cyclophosphamide and etoposide results in predictable drug levels and durable long-term survival in lymphoma patients undergoing autologous stem cell transplantation. Biol Blood Marrow Transplant. 2012;18:1287–1294.
   PubMed Web of Science ®Google Scholar
• Pasquini MRJ, Flowers C. Matched pair comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) conditioning regimen prior to autologous hematopoietic cell transplantation (autoHCT) for lymphoma. BMT Tandem Meetings. 2014;20:S162.
   Google Scholar
• Nieto Y, Bassett R, Anderlini P, et al. Prospective phase 2 trial of high-dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with autologous stem-cell transplant (ASCT) without post-ASCT maintenance, in hodgkins lymphoma patients at high risk of post-transplant recurrence comparison with a concurrent matched cohort treated with BEAM. Blood. 2015;126(Suppl):1980 (abstr 1980).
   Google Scholar
• Leoni LM, Bailey B, Reifert J, et al. Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res. 2008;14:309–317.
   PubMed Web of Science ®Google Scholar
• Visani G, Malerba L, Stefani PM, et al. BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients. Blood. 2011;118:3419–3425.
   PubMed Web of Science ®Google Scholar
• Visani G, Stefani PM, Capria S, et al. Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. Blood. 2014;124:3029–3031.
   PubMed Web of Science ®Google Scholar
• Isidori A, Guidi S, Scalzulli PR, et al. Benda-BEAM high-dose therapy prior to auto-SCT is effective in resistant/relapsed DLBCL. Blood. 2015;126(Suppl):1999 (abstr 1999).
   Google Scholar
• Noesslinger T, Moestl M, Tinchon C, et al. Autologous stem cell transplantation with Benda-BEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) in aggressive non Hodgkin and Hodgkińs lymphoma. Blood. 2014;124:3982–3982.
   PubMed Web of Science ®Google Scholar
• Martín A, Redondo AM, Valcárcel D, et al. A phase 2 study from Spanish Geltamo group investigating the efficacy and safety of bendamustine as part of conditioning regimen for autologous stem-cell transplantation in patients with aggressive lymphomas: second interim analysis. Blood. 2014;124:2524–2524.
   Google Scholar
• Musso M, Messina GD, Renzo ND, et al. Improved outcome of patients with relapsed/refractory Hodgkin lymphoma with a new fotemustine-based high-dose chemotherapy regimen. Br J Haematol. 2016;172:111–121.
   PubMed Web of Science ®Google Scholar
• Musso M, Scalone R, Marcacci G, et al. Fotemustine plus etoposide, cytarabine and melphalan (FEAM) as a new conditioning regimen for lymphoma patients undergoing auto-SCT: a multicenter feasibility study. Bone Marrow Transplant. 2010;45:1147–1153.
   PubMed Web of Science ®Google Scholar
• Hansen HH, Selawry OS, Pajak TF, et al. The superiority of CCNU in the treatment of advanced Hodgkin's disease: cancer and leukemia group B study. Cancer. 1981;47:14–18.
   PubMed Web of Science ®Google Scholar
• Stuart MJ, Chao NS, Horning SJ, et al. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biol Blood Marrow Transplant. 2001;7:552–560.
   PubMed Web of Science ®Google Scholar
• Perz JB, Giles C, Szydlo R, et al. LACE-conditioned autologous stem cell transplantation for relapsed or refractory Hodgkin’s lymphoma: treatment outcome and risk factor analysis in 67 patients from a single centre. Bone Marrow Transplant. 2007;39:41–47.
   PubMed Web of Science ®Google Scholar
• Ramzi M, Mohamadian M, Vojdani R, et al. Autologous noncryopreserved hematopoietic stem cell transplant with CEAM as a modified conditioning regimen in patients with Hodgkin lymphoma: a single-center experience with a new protocol. Exp Clin Transplant. 2012;10:163–167.
   PubMed Web of Science ®Google Scholar
• Kothari J, Foley M, Peggs KS, et al. Excess late gastrointestinal toxicity associated with leam conditioning compared to BEAM for autologous stem cell transplantation in lymphoma, a single institution experience. Blood. 2014;124:5898–5898.
   Google Scholar
• Kim JW, Lee HJ, Yi HG, et al. Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. Am J Hematol. 2012;87:479–483.
   PubMed Web of Science ®Google Scholar
• Sellner L, Boumendil A, Finel H, et al. Thiotepa-based high-dose therapy for autologous stem cell transplantation in lymphoma: a retrospective study from the EBMT. Bone Marrow Transplant. 2016;51:212–218.
   PubMed Web of Science ®Google Scholar
• Decaudin D, Mounier N, Tilly H, et al. (90)Y ibritumomab tiuxetan (Zevalin) combined with BEAM (Z -BEAM) conditioning regimen plus autologous stem cell transplantation in relapsed or refractory low-grade CD20-positive B-cell lymphoma. A GELA phase II prospective study. Clin Lymphoma Myeloma Leuk. 2011;11:212–218.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Palmer JM, Tsai NC, et al. Matched-cohort analysis of autologous hematopoietic cell transplantation with radioimmunotherapy versus total body irradiation-based conditioning for poor-risk diffuse large cell lymphoma. Biol Blood Marrow Transplant. 2012;18:441–450.
   PubMed Web of Science ®Google Scholar
• Shimoni A, Avivi I, Rowe JM, et al. A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma. Cancer. 2012;118:4706–4714.
   PubMed Web of Science ®Google Scholar
• Vose JM, Carter S, Burns LJ, et al. Phase III randomized study of rituximab/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol. 2013;31:1662–1668.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385:1853–1862.
   PubMed Web of Science ®Google Scholar